Anticoagulant Reversal
|
|
- Irma Lamb
- 8 years ago
- Views:
Transcription
1 No Conflicts of Interest to Report Anticoagulant Reversal Matthew Bondi Pharm.D., BCPS March 14, 2015 Matthew Bondi Pharm.D., BCPS. Clinical Pharmacist Sparrow Hospital Ph Objectives» To review guidelines for reversal of anticoagulation with or without bleeding.» To describe the various agents available for assisting in anticoagulation therapy reversal» To illustrate the use of anticoagulation reversal guidelines through a patient case 54 y/o female with Elevated INR on Admission» HPI MM is a 85 kg, 58yo female with h/o Lupus, Rheumatoid Arthritis, Osteoarthritis, Mixed Connective Tissues Disease, h/o CVA, h/o L DVT s/p L BKA, Fibromyalgia, Hypertension, and IBS who comes as a transfer from another Hospital for septic shock.» She initially went to ED late evening on 7/23/13 for severe constant abdominal pain which occurred about 4 hours after ingestion of Bratwurst Sausage. She also had some nausea and vomiting x2 as well.» Her labs at the other hospital showed:» ALP 259, AST 85, ALT 45, Total Bili 1.4, Albumin 4.2, Creatinine 1.3, BUN 22, Hgb 13.6, Troponin 0.012, INR 9.12, aptt 52.7,» WBC 13.9, U/A with many bacteria with large amt Leukocyte Esterase and Positive Nitrite. 54 y/o female with Elevated INR on Admission» She was started on IV ceftriaxone and her BP continued to drop to SBP in 70s» She was transferred to Sparrow ICU for further management.» In examination, she complains of abdominal pain and diffuse joint pain from her arthritis as well. She denies any pain with urination, however does have some lower abdominal pain as well. She appears to be drowsy and her BP is in 50 60s despite levophed 30mcg.» Pharmacy was contacted for anticoagulation reversal» Patient needs central line and arterial line. Reversal of What?» Unfractionated Heparin» LMWH» Warfarin» Direct Thrombin Inhibitors» Factor Xa Inhibitors» Antiplatelet agents Speaker: Matthew Bondi, PharmD 1
2 Why Reverse?»Emergent Reversal vs. Periprocedural»Bleeding vs. non bleeding»high INR vs. Low INR»Heparin vs. LMWH vs. VKA vs. Target Directed Choice of Reversal Strategy»Pharmacology of the agent»clinical urgency»severity of bleeding Comparison of Select Reversal Agents Heparin and LMWH» Heparin and Low Molecular Weight Heparins (LMWH) (i.e. enoxaparin (Lovenox )» Indications» DVT/PE» Afib» ACS» Warfarin bridge Anticoagulation Therapy: A Point of Care Guide edited by William E. Dager, Michael P. Gulseth, Edith A. Nutescu Protamine for Heparin Reversal» Mechanism» Anticoagulant when given w/o heparin» Forms a stable complex with heparin neutralizing anticoagulant effects of both» Dosing» 1 mg protamine neutralizes 100 units of heparin» Max single dose: 50 mg»infusions: count amount given in preceding hours»reduce dose as elapsed time since heparin given increases Protamine for LMWH Reversal»Can t fully reverse»excessive protamine doses may worsen bleeding»reduce dose as elapsed time since LMWH given increases» Enoxaparin (Lovenox ) reversal»<8 hours 1 mg protamine = 1 mg enoxaparin»> 8 hours 0.5 mg protamine = 1 mg enoxaparin Speaker: Matthew Bondi, PharmD 2
3 Slide 11 BM1
4 Administration of Protamine Oral Anticoagulants» Inject slowly; further dilution unnecessary» Max of 50 mg over 10 minutes» Repeat aptt 5 15 minutes after dose, redose prn» Too rapid administration» Hypotension» Anaphylactic reactions» Heparin neutralization in 5 mins» May be diluted in D5W or NS Fresh Frozen Plasma Fresh Frozen Plasma Procoagulant Factors Cryoprecipitate Prothrombin Complex Concentrate Activated Prothrombin Complex Concentrate rfviia» Obtained from human blood» Contains all the clotting factors» Dosing based on weight» Expressed as the volume or # of units of the product.» ml/kg % increase in plasma levels of clotting factors. Fresh Frozen Plasma» Clinical practice: 2 units commonly prescribed.» Could be inadequate for patients with larger body weight» mL per unit» Potentially large fluid volume»can be beneficial in patient with volume loss»could be problematic in patient with fluid overload.» Disadvantages Fresh Frozen Plasma» Need for thawing: delays administration» Large fluid volume» Potential (although low) risk of transmission of infectious disease» Transfusion reactions» Takes longer to work than other options Speaker: Matthew Bondi, PharmD 3
5 Prothrombin Complex Concentrates» Concentrated pooled plasma products» Contain 3 or 4 factors» Activated versus not activated» Also may contain Proteins C,S and Z» Regulate the effects of coagulation factors» In some cases have heparin and antithrombin Prothrombin Complex Concentrates» 3 factor PCCs» Bebulin» Profilnine SD» Factors II,IX, and X» Still contains factor VII but insignificant» Activation required via the coagulation cascade. 3 Factor PCC: Bebulin» Part of Rapid Reversal Protocol» INR > 20 or serious bleeding» Life threatening bleeding regardless of INR» Concomitant use of FFP and Vit K» Dosing of PCC is currently a recommendation of 30 units/kg Prothrombin Complex Concentrate» The concentrations of the clotting factors in the products varies depending on manufacture and lot» Doses are always expressed in units of the factor IX component.» Round to nearest vial size available Comparison of PCCs to FFP» Correct the INR more rapidly than FFP» Prep time for PCCs is shorter» Higher concentration of clotting factors» Thrombotic events possible with PCCs Speaker: Matthew Bondi, PharmD 4
6 » Effectiveness of PCC for rapid reversal of INR in patients with AAICH» Used a 3 Factor PCC Profilnine» Retrospective analysis of 19 patients with AAICH Jan 2005 through May 2006» Compared» patients treated with FFP + Vit K» Patients treated with PCC + FFP + Vit K» Mean INR on admission for both groups» Time to reach the mean target INR for both groups» # of patient at Target INR in 3 4 hours.» Reported death, and thrombotic complications» Treatment Protocol for FFP Group» Hold all Anticoagulants» Vit K 10mg IV» FFP ml/kg» INR checked at presentation» INR checked at completion of therapy» 2 3 hours after initiation of therapy» FFP repeated if required» Serial INRs obtained at 2 3 hours until target INR» Treatment Protocol for PCC Group» Hold all anticoagulants» Vit K 10 mg IV» Profilnine (PCC)» 25 units/kg IVP INR < 4» 50 units/kg IVP INR >4» Further doses after INR check 3 hours after initial dose.» FFP given same as FFP group» INR checked at presentation» INR checked at completion of therapy (Profilnine)» 1 2 hours after initiation of therapy» Serial INRs obtained at 2 3 hours until target INR» Results» No difference in initial INR between groups» Significant reduction in INR was observed in both groups after respective therapy» FFP + Vit K» 1.84 ± 0.31 to a mean value 1.34 ± 0.08 (p<0.05)» PCC + FFP + VitK» 2.44 ± 1.48 to a mean value 1.34 ± 0.07 (p<0.005)» Results» 3 patients in FFP group (33%) and 8 in the PCC group (80%) reached their target INR in 3 4 hours after initiation of therapy (p=0.012)» Time to reach INR of 1.4 or less (p < 0.05)» FFP group = 8.52 ± 5.6 h» PCC group = 4.25 ± 2.12 h Speaker: Matthew Bondi, PharmD 5
7 4 Factor PCCs» Conclusions» PCC is effective in rapidly reversing the effects of anticoagulation both in terms of absolute time required and the rate of correction of INR.» The use of PCC in combination with FFP and Vit K results in decreased time required for correction of coagulopathy in emergency situations compared to FFP and Vit K alone.» Factors II, IX, X and VII» Activation required via the coagulation cascade» Available in Europe and Canada for several years» Available in US since spring Factor PCCs 3 vs. 4 Factor PCC products» Lack of studies comparing activity of 3 factor PCCs to 4 factor PCCs» Lack of studies evaluating clinical outcomes of the PCCs.» Thrombotic complications» VTE, DIC, microvascular thrombosis» MI Included 18 Studies representing 654 patients ICH, Urgent Surgery, Invasive procedure or GI Bleeding No RCCT; No direct comparisons Typically Elderly Patients Baseline INRs 3PCC : 3.3 to 5.1 4PCC : 2.3 greater than 20 INR within 1 hour of PCC administration 3PCC: 1.2 to 1.9 4PCC: 1 to 1.9 Speaker: Matthew Bondi, PharmD 6
8 INR < 1.5 within 1 hour after PCC administration 3PCC: 6 of 9 Study groups (67%) 4PCC: 12 of 13 Study groups (92%) Conclusions 4 factor PCCs are more effective than 3 factor PCCs in decreasing the INR to < within one hour of administration Limitations No direct comparisons of 3 factor PCC vs. 4 factor PCC A surrogate outcome (INR reversal to < 1.5 in one hour) to compare effectiveness in lieu of clinical outcomes Factor Xa Inhibitors» Available products» Eliquis (apixaban)» Xarelto (rivaroxaban)» Indications» DVT/PE (treat & prevent)» Nonvalvular Afib» Dose adjusted for renal insufficiency» Administration of rivaroxaban» Administer doses >15 mg with food» May be crushed and mixed in apple sauce Oral Direct Thrombin Inhibitor» Available products» Pradaxa (Dabigatran)» Indications» DVT/PE (treat)» Nonvalvular Afib» Adjust for renal insufficiency» Administration» Take with or without food» Do not break capsules» Dyspepsia common Reversal of Target Specific Oral Anticoagulants for Life threatening Bleeding Non life Threatening Bleeding No specific antidote for reversing rivaroxaban, apixaban, or dabigatran. No available data supporting the use of FFP, rfviia (Novo Seven ), or 3 Factor PCC (Bebulin ) in humans for reversal of the TSOACs RBCs and other supportive care as needed Dabigatran IS removed by hemodialysis (60% of the drug removed over 2 3 hrs) Rivaroxaban and apixaban ARE NOT removed by hemodialysis. 4F PCC (Kcentra ) has not been studied in patients < 18 years» Delay next dose or discontinue the anticoagulant» Symptomatic treatment» Fluid replacement and hemodynamic support as needed» Blood product transfusion as needed Speaker: Matthew Bondi, PharmD 7
9 Warfarin (Coumadin)» Inhibits Vitamin K dependent clotting factors (Factors II, VII, IX, X as well as Proteins C and S)» Indications» DVT/PE» Afib» Heart valves» INR monitoring» Drug and dietary interactions» Teratogenic» Delayed and unpredictable effects Reversal of Warfarin Without Significant Bleeding * Doses have been rounded to comply with commercially available Vitamin K 1 dosage forms. Reversal of Warfarin With Significant Bleeding Reversal of Warfarin for Surgical Procedure * Doses have been rounded to comply with commercially available Vitamin K 1 dosage forms. ** Vitamin K 1 for infusion should be mixed in D5W 50 ml and given over 30 minutes. * Doses have been rounded to comply with commercially available Vitamin K 1 dosage forms. ** Vitamin K 1 for infusion should be mixed in D5W 50 ml and given over 30 minutes. 54 y/o female with Elevated INR on Admission» HPI MM is a 85 kg, 58yo female with h/o Lupus, Rheumatoid Arthritis, Osteoarthritis, Mixed Connective Tissues Disease, h/o CVA, h/o L DVT s/p L BKA, Fibromyalgia, Hypertension, and IBS who comes as a transfer from another Hospital for septic shock.» She initially went to ED late evening on 7/23/13 for severe constant abdominal pain which occurred about 4 hours after ingestion of Bratwurst Sausage. She also had some nausea and vomiting x2 as well.» Her labs at the other hospital showed:» ALP 259, AST 85, ALT 45, Total Bili 1.4, Albumin 4.2, Creatinine 1.3, BUN 22, Hgb 13.6, Troponin 0.012, INR 9.12, aptt 52.7,» WBC 13.9, U/A with many bacteria with large amt Leukocyte Esterase and Positive Nitrite. 54 y/o female with Elevated INR on Admission» She was started on IV ceftriaxone and her BP continued to drop to SBP in 70s» She was transferred to Sparrow ICU for further management.» In examination, she complains of abdominal pain and diffuse joint pain from her arthritis as well. She denies any pain with urination, however does have some lower abdominal pain as well. She appears to be drowsy and her BP is in 50 60s despite levophed 30mcg.» Patient needs central line and arterial line. Speaker: Matthew Bondi, PharmD 8
10 54 y/o female with Elevated INR on Admission 54 y/o female with Elevated INR on Admission * Doses have been rounded to comply with commercially available Vitamin K 1 dosage forms. ** Vitamin K 1 for infusion should be mixed in D5W 50 ml and given over 30 minutes.» Give Vitamin K 5 10mg IVPB x1» INR >6» Kcentra 50 units/kg (max 5000 units)»4250 units (85 kg female)»dose rounded to nearest vials» Check INR ½ to 1 hour after Kcentra infused, then every 12 hours x2.» Could give FFP if INR remains elevated. Trauma Patients» If receiving warfarin at home and INR < 1.5» Reversal not indicated» Recheck INR in 24 h» Treatment recommendations differ based on whether the patient has evidence of either:» Head trauma» CT positive for bleed Trauma Patients» Patient w/o head trauma/ct negative for bleed» INR <3: reversal not indicated» INR > 3»But < 10 & not symptomatic: reversal not indicated»inr > 10 & not symptomatic: Vitamin K mg PO»INR > 3 & symptomatic: Vitamin K 10 mg PO or IV» Hold warfarin and recheck INR in 12 or 24 hours Trauma Patients» Patient with head trauma or CT positive for bleed» Hold warfarin» Vitamin K 10 mg IVPB» Administer 4F PCC (Kcentra)» If INR > 1.5 thirty min after Kcentra» Give FFP 2 4 units» Recheck INR in 30 minutes» Recheck INR q 6 h X 24 h, redose vitamin K prn Trauma Patients» Factor Xa Inhibitors (rivaroxaban, apixaban)» When was the last dose taken»greater than 24 hours (rivaroxaban) (renal function)»greater than 12 hours (apixaban)» Kcentra 50 units/kg (max 5000units)» Vitamin K administration: Not necessary Speaker: Matthew Bondi, PharmD 9
11 Trauma Patients» Direct Thrombin Inhibitors (dabigatran)» When was the last dose taken»greater than 12 hours (renal function)» Feiba (activated PCC) units/kg x1»may repeat; Max 200 units/kg/day» 3 & 4 PCCs appear ineffective» Dabigatran is dialyzable (approx 60%) Administration of Vitamin K» Recommended routes» Oral»Tablets or injection diluted in juice»onset: 6 10 hours; Peak: hours» Intravenous (IV)»Diluted in 50 ml D5W given over 30 min.»onset: 1 2 hours; Peak: hours» Avoid SubQ or IM administration Administration of Kcentra» Must also give vitamin K in warfarin patients» Administer via separate IV line» Administration rate is 0.12 ml/kg/min ( 3 units/kg/min) up to 8.4 ml/min ( 210 units/min)» Repeat INR 30 minutes after 4F PCC then every 12 hours X 2, daily X 3 5 days» No repeat doses» If INR does not correct consider 2 4 units FFP Activated PCC (Feiba )» Contains Factors II, VII, IX and X» Factor VII is activated.» Concern for thrombotic events.» Dosing: units» Infusion NTE 2 units/kg/min Administration of Feiba» Must be brought to room temperature prior to reconstitution» Administer via separate IV line» Maximum infusion rate is 2 units/kg/minute» Decrease infusion rate if HA, flushing, changes in BP/HR» Infusion must be completed within 3 hours of reconstitution Questions? Matthew Bondi Pharm.D., BCPS. Clinical Pharmacist Sparrow Hospital Matthew.bondi@sparrow.org Ph Speaker: Matthew Bondi, PharmD 10
12 Speaker: Matthew Bondi, PharmD 11
LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationDisclosures. Objective (NRHS) Self Assessment #2
Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More information10/16/2013. Reversal of Anticoagulants: Something New Under the Sun? Disclosures. Pharmacist Objectives
Reversal of Anticoagulants: Something New Under the Sun? Zachariah Thomas, PharmD, BCPS Clinical Associate Professor Ernest Mario School of Pharmacy Rutgers, the State University of New Jersey Clinical
More informationOral anticoagulants new and old: bleeding risk and management strategies. Logan Tinsen Pharm.D. Benefis Hospitals
Oral anticoagulants new and old: bleeding risk and management strategies Logan Tinsen Pharm.D. Benefis Hospitals Disclaimer! I am not receiving any compensation from any drug company! Any opinions I may
More informationCONTEMPORARY REVERSAL OF ANTICOAGULATION
CONTEMPORARY REVERSAL OF ANTICOAGULATION Michael S. McHale, M.D., F.A.C.P. Avera Medical Group Hematology & Oncology Medications Coumadin / Warfarin Unfractionated Heparin Low Molecular Weight Heparin
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationDisclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.
Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize
More informationHow does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?
Anticoagulation reversal Vitamin K antagonists and New Oral Anticoagulants Robert Orman, MD Warfarin How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really
More informationAdvances in An+coagula+on
Advances in An+coagula+on Laurajo Ryan PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Aus+n College of Pharmacy UTHSCSA School of Medicine Pharmcotherapy Research Educa+on
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationTitle of Guideline. Thrombosis Pharmacist)
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationMANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationRecommendation for the Reversal of Novel Anticoagulants in Emergent Situations
Lauren Edwards PharmD Candidate 2016 Truman Medical Center, Lakewood Preceptor: Dr. Melissa Gabriel June 11, 2015 Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations Background
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationHigh Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationHow To Increase Warfarin
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology daniel.forman@readinghealth.org 610 509 5067 cell RHS Anticoagulation
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationPulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationEmerging therapies for Intracerebral Hemorrhage
Emerging therapies for Intracerebral Hemorrhage Chitra Venkat, MBBS, MD, MSc. Associate Professor of Neurology and Neurological Sciences Stroke and Neurocritical Care. Stanford University Learning objectives
More informationTo assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationClinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More information23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist
Implications for the Gastroenterologist Dr. Daniel Sadowski Royal Alexandra Hospital Edmonton, Ab. No financial interests I am not a hematologist 65 y.o. male referred for iron deficiency anemia (FIT positive)
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationDirected to Dr. Carrier from NBRHC audience Q: In patients with GI Bleed history, would you suggest Apixaban for newly diagnosed patients
9 th Annual CBS/ORBCoN Transfusion Medicine Videoconference Symposium: April 9, 2014 Question and Answer Period Morning Session: Directed to Dr. Carrier from Dr. Bormanis Q: If the half lives are similar
More informationAdvanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationRx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More information